Journal article
Potential Role of Selenium in the Treatment of Cancer and Viral Infections
International journal of molecular sciences, Vol.23(4), p.2215
02/17/2022
DOI: 10.3390/ijms23042215
PMCID: PMC8879146
PMID: 35216330
Abstract
Selenium has been extensively evaluated clinically as a chemopreventive agent with variable results depending on the type and dose of selenium used. Selenium species are now being therapeutically evaluated as modulators of drug responses rather than as directly cytotoxic agents. In addition, recent data suggest an association between selenium base-line levels in blood and survival of patients with COVID-19. The major focus of this mini review was to summarize: the pathways of selenium metabolism; the results of selenium-based chemopreventive clinical trials; the potential for using selenium metabolites as therapeutic modulators of drug responses in cancer (clear-cell renal-cell carcinoma (ccRCC) in particular); and selenium usage alone or in combination with vaccines in the treatment of patients with COVID-19. Critical therapeutic targets and the potential role of different selenium species, doses, and schedules are discussed.
Details
- Title: Subtitle
- Potential Role of Selenium in the Treatment of Cancer and Viral Infections
- Creators
- Aseel O Rataan - Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy University of Iowa, Iowa City, IA 52242, USASean M Geary - Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy University of Iowa, Iowa City, IA 52242, USAYousef Zakharia - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USAYoucef M Rustum - Roswell Park Comprehensive Cancer Center, Department of Pharmacology & Therapeutics, Buffalo, NY 14203, USAAliasger K Salem - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
- Resource Type
- Journal article
- Publication Details
- International journal of molecular sciences, Vol.23(4), p.2215
- DOI
- 10.3390/ijms23042215
- PMID
- 35216330
- PMCID
- PMC8879146
- NLM abbreviation
- Int J Mol Sci
- ISSN
- 1661-6596
- eISSN
- 1422-0067
- Language
- English
- Date published
- 02/17/2022
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering; Internal Medicine
- Record Identifier
- 9984221730902771
Metrics
100 Record Views